ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

Phase 3

Completed

Conditions: Dyslipidemia

Interventions: Drug: niacin extended-release (NER)
Drug: aspirin (ASA)
Drug: aspirin placebo (ASA Pbo)

First Posted Date: 2008-02-29

Last Posted Date: 2009-09-02

Lead Sponsor: Abbott

Target Recruit Count: 277

Registration Number: NCT00626392

A Study of Leuprolide to Treat Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide acetate - Formulation A
Drug: Leuprolide acetate - Formulation B

First Posted Date: 2008-02-29

Last Posted Date: 2011-07-19

Lead Sponsor: Abbott

Target Recruit Count: 310

Registration Number: NCT00626431

Locations: 🇺🇸
Site Reference ID/Investigator# 8699, Torrance, California, United States
🇺🇸
Site Reference ID/Investigator# 8674, Los Angeles, California, United States
🇺🇸
Site Reference ID/Investigator# 8567, Columbus, Ohio, United States

and more 60 locations

Creon in HIV Patients With Steatorrhea

Phase 3

Terminated

Conditions: Steatorrhea

Interventions: Drug: Placebo
Drug: Creon 25000

First Posted Date: 2008-02-25

Last Posted Date: 2011-08-01

Lead Sponsor: Abbott

Target Recruit Count: 34

Registration Number: NCT00623025

Locations: 🇷🇴
Site Reference ID/Investigator# 59363, Craiova, Romania
🇷🇴
Site Reference ID/Investigator# 59364, Bucharest, Romania

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

Phase 3

Terminated

Conditions: Chronic Kidney Disease (CKD) Stage 5
Hypertrophy, Left Ventricular

Interventions: Drug: paricalcitol injection 4 mcg/mL
Drug: Placebo Injection 4 mcg/mL

First Posted Date: 2008-02-15

Last Posted Date: 2012-01-20

Lead Sponsor: Abbott

Target Recruit Count: 12

Registration Number: NCT00616902

Locations: 🇺🇸
North American Research Institute - California Kidney Specialist, San Dimas, California, United States
🇺🇸
National Institute of Clinical Research, Los Angeles, California, United States
🇺🇸
Southwest Kidney Institute, Tempe, Arizona, United States

and more 61 locations

Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Adalimumab

First Posted Date: 2008-01-29

Last Posted Date: 2011-06-21

Lead Sponsor: Abbott

Target Recruit Count: 88

Registration Number: NCT00603993

Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children

Completed

Conditions: Respiratory Syncytial Viruses
Respiratory Tract Infection

Interventions: Procedure: Samples collection for viral diagnosis
Procedure: Lung Function Analysis

First Posted Date: 2008-01-03

Last Posted Date: 2011-12-19

Lead Sponsor: Abbott

Target Recruit Count: 310

Registration Number: NCT00585481

Locations: 🇧🇷
Site Ref # / Investigator 6185, Curitiba, PR, Brazil
🇧🇷
Site Ref # / Investigator 6189, Ribeirao Preto, SP, Brazil

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment

Phase 3

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Biological: adalimumab
Drug: placebo (vehicle ointment)
Drug: Calcipotriol/Betamethasone Ointment

First Posted Date: 2007-12-17

Last Posted Date: 2011-04-13

Lead Sponsor: Abbott

Target Recruit Count: 730

Registration Number: NCT00574249

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

Phase 3

Completed

Conditions: Psoriasis

Interventions: Biological: adalimumab

First Posted Date: 2007-12-04

Last Posted Date: 2011-04-12

Lead Sponsor: Abbott

Target Recruit Count: 152

Registration Number: NCT00566722

Locations: 🇨🇦
Siena Medical Research, Montreal, Quebec, Canada
🇨🇦
Eastern Canada Cutaneous Research Associates, Halifax, Nova Scotia, Canada
🇨🇦
Stratica Medical, Edmonton, Alberta, Canada

and more 22 locations

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Biological: Placebo
Biological: ABT-874

First Posted Date: 2007-11-26

Last Posted Date: 2011-08-23

Lead Sponsor: Abbott

Target Recruit Count: 246

Registration Number: NCT00562887

Locations: 🇨🇦
Site Ref # / Investigator 17901, Toronto, Ontario, Canada
🇺🇸
Site Ref # / Investigator 6691, Atlanta, Georgia, United States
🇺🇸
Site Ref # / Investigator 6670, Hamden, Connecticut, United States

and more 58 locations

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-089
Drug: placebo

First Posted Date: 2007-11-08

Last Posted Date: 2011-08-23

Lead Sponsor: Abbott

Target Recruit Count: 337

Registration Number: NCT00555204

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy